Evidence map›Paper›PMID 27152638›Full record

ReviewAnnals of the New York Academy of Sciences2016

Targeted heat shock protein 72 for pulmonary cytoprotection.

Missag H Parseghian, Stephen T Hobson, Richard A Richieri

Open access · greenAbstract readReview
In one paragraph

Review in Annals of the New York Academy of Sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Mechanism of Phosgene-Induced Acute Lung Injury and Treatment Strategy.International journal of molecular sciences · 2021
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Missag H ParseghianRubicon Biotechnology, Lake Forest, California.
Stephen T HobsonRubicon Biotechnology, Lake Forest, California.
Richard A RichieriRubicon Biotechnology, Lake Forest, California.
Rubicon Biotechnology (United States) · US

Funding

Intracellular targeting Hsp70 for pulmonary cytoprotection after toxin inhalationR21ES024028 · NIEHS · RUBICON BIOTECHNOLOGY, INC. · PI NISHIMURA, ROBERT, PARSEGHIAN, MISSAG HAGOP · 2013 to 2014
$669k
NIEHS NIH HHS R21 ES024028
6 · The paper itself

Abstract

Heat shock protein 72 (HSP72) is perhaps the most important member of the HSP70 family of proteins, given that it is induced in a wide variety of tissues and cells to combat stress, particularly oxidative stress. Here, we review independent observations of the critical role this protein plays as a pulmonary cytoprotectant and discuss the merits of developing HSP72 as a therapeutic for rapid delivery to cells and tissues after a traumatic event. We also discuss the fusion of HSP72 to a cell-penetrating single-chain Fv antibody fragment derived from mAb 3E10, referred to as Fv-HSP70. This fusion construct has been validated in vivo in a cerebral infarction model and is currently in testing as a clinical therapeutic to treat ischemic events and as a fieldable medical countermeasure to treat inhalation of toxicants caused by terrorist actions or industrial accidents.

Indexed as

CytoprotectionMolecular Targeted TherapyAnimalsHSP72 Heat-Shock ProteinsHumansLungModels, BiologicalStress, PhysiologicalHSP72 Heat-Shock Proteinsapoptosis inhibitorHSP70HSP72medical countermeasureoxidative stressreperfusion therapy

Identifiers

PMID27152638
PMCPMC4940224
OpenAlexW2346656247

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.